Previous Article | Next Article ![]()
Mol Cell Biol, July 1998, p. 4262-4271, Vol. 18, No. 7
Howard Hughes Medical Institute and
Department of Pharmacology, University of Colorado School of
Medicine, Denver, Colorado 80262
Received 26 January 1998/Returned for modification 10 March
1998/Accepted 21 April 1998
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Activated Polo-Like Kinase Plx1 Is Required at
Multiple Points during Mitosis in Xenopus laevis
SUMMARY
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
ACKNOWLEDGMENTS
REFERENCES
SUMMARY
|
|
|---|
Entry into mitosis depends upon activation of the dual-specificity phosphatase Cdc25C, which dephosphorylates and activates the cyclin B-Cdc2 complex. Previous work has shown that the Xenopus polo-like kinase Plx1 can phosphorylate and activate Cdc25C in vitro. In the work presented here, we demonstrate that Plx1 is activated in vivo during oocyte maturation with the same kinetics as Cdc25C. Microinjection of wild-type Plx1 into Xenopus oocytes accelerated the rate of activation of Cdc25C and cyclin B-Cdc2. Conversely, microinjection of either an antibody against Plx1 or kinase-dead Plx1 significantly inhibited the activation of Cdc25C and cyclin B-Cdc2. This effect could be reversed by injection of active Cdc25C, indicating that Plx1 is upstream of Cdc25C. However, injection of Cdc25C, which directly activates cyclin B-Cdc2, also caused activation of Plx1, suggesting that a positive feedback loop exists in the Plx1 activation pathway. Other experiments show that injection of Plx1 antibody into early embryos, which do not require Cdc25C for the activation of cyclin B-Cdc2, resulted in an arrest of cleavage that was associated with monopolar spindles. These results demonstrate that in Xenopus laevis, Plx1 plays important roles both in the activation of Cdc25C at the initiation of mitosis and in spindle assembly at late stages of mitosis.
INTRODUCTION
|
|
|---|
Progression through the eucaryotic cell cycle is controlled by the activation of several cyclin-dependent kinases (cdks) at specific points in the cycle. To maintain genomic stability, surveillance mechanisms known as checkpoints monitor the completion of essential events to prevent cell cycle progression if DNA is damaged, unreplicated, or improperly assembled on the mitotic spindle (reviewed in references 6 and 20). The biochemistry of cell cycle-dependent checkpoints is best characterized during G2 phase, when checkpoints determine whether a cell enters mitosis. The cdk that drives the G2/M transition, cyclin B-Cdc2, is not activated on schedule if DNA is damaged or if DNA replication is incomplete (2; reviewed in reference 7). Both the DNA damage and DNA replication checkpoints regulate cyclin B-Cdc2 activation in part through the phosphatase Cdc25C. Throughout late S and early G2 phases, cyclin B is synthesized and immediately complexes with Cdc2, which is kept catalytically inactive by phosphorylation of Tyr15 and Thr14 in the ATP-binding site (12, 16, 29). This phosphorylation and inactivation is catalyzed by the protein kinases Wee1 and Myt1 (42, 45), and dephosphorylation and activation of cyclin B-Cdc2 is catalyzed by the phosphatase Cdc25C (4, 13, 37).
Studies on vertebrate Cdc25C have shown that its ability to dephosphorylate cyclin B-Cdc2 and initiate mitosis is regulated by two distinct mechanisms. Activation of Cdc25C requires phosphorylation on specific serine and threonine sites (21, 25, 31), and this phosphorylation fails to occur if DNA synthesis is incomplete and the replication checkpoint is activated. It has also been suggested that the rate of phosphorylation of Cdc2 on tyrosine is increased when DNA replication is incomplete (52). The other Cdc25C regulatory mechanism is implicated in the G2 DNA damage checkpoint and involves activation of the kinase Chk1 to phosphorylate Cdc25C at a specific site, an event that promotes the binding of 14-3-3 proteins (10, 47, 51). Although this binding does not directly inhibit the phosphatase activity of Cdc25C in vitro, the proximity of the 14-3-3 binding site to a nuclear localization signal suggests that it may affect the colocalization of Cdc25C with its cdk substrate in the nucleus (10, 47, 51).
To better understand the DNA replication checkpoint, it is necessary to define the phosphorylation pathway by which Cdc25C becomes activated at the G2/M transition. Cyclin B-Cdc2 itself is able to phosphorylate Cdc25C at the activating sites, forming a positive feedback loop that contributes to the abrupt transition from G2 into M phase (23). However, a variety of evidence indicates that initial phosphorylation of Cdc25C at the G2/M transition occurs prior to cyclin B-Cdc2 activation, and full phosphorylation and activation of Cdc25C can be obtained in microcystin-treated egg extracts devoid of Cdc2 and Cdk2 (24). This has focused attention on the identification of other protein kinases that might function as "trigger" kinases for Cdc25C activation and might be subject to inhibition when the DNA replication checkpoint is activated. Recently, it was reported that the Xenopus polo-like kinase (plk), Plx1, can phosphorylate and activate Cdc25C in vitro (30). However, it is not known if Plx1 activity increases during the Xenopus cell cycle or if its activity is required for Cdc25C activation in vivo. Genetic studies with Drosophila melanogaster, Saccharomyces cerevisiae, and Schizosaccharomyces pombe implicate plk activity in centrosome functions, spindle assembly, and cytokinesis events, and mutations in plks usually correlate with defects in spindles or septum formation (39, 44; reviewed in references 14 and 33). These phenotypes are more consistent with a kinase that functions late in mitosis rather than during the initial stages of mitosis at the G2/M transition, and indeed, in D. melanogaster, polo activity peaks at the late-anaphase/telophase border, later than cyclin B-Cdc2 activity (8). In contrast, in mammalian cells, Plk1 activity peaks in concert with that of cyclin B-Cdc2 at the onset of mitosis (15, 17, 36). In these cells, Plk1 colocalizes and interacts with various components of the mitotic spindle apparatus, and moreover, microinjection of an antibody to Plk1 blocks cells in G2 or in a psuedomitotic state, with monopolar spindles (15, 32, 36). These considerations make it imperative to determine whether Plx1 activity is regulated during the Xenopus cell cycle and whether it is required for Cdc25C activation and spindle assembly events during mitosis.
MATERIALS AND METHODS
|
|
|---|
Preparation of oocytes and oocyte extracts.
Xenopus
laevis females, obtained from Xenopus I (Ann Arbor, Mich.), were
primed with 35 IU of pregnant mare's serum gonadotropin 3 days prior
to an experiment. Stage VI oocytes were dissected manually and cultured
in modified Barth's solution. Unless otherwise stated, maturation was
induced by treatment with 3.2 µM progesterone. Samples were
microinjected with a volume of 50 nl with a Medical Systems Corp.
(Greenvale, N.Y.) PLI-100 apparatus. Oocytes were harvested at the
indicated times, frozen in dry ice, and stored at
80°C until
further analysis. For preparation of extracts, frozen oocytes were
homogenized in 20 µl of extraction buffer per oocyte and centrifuged
for 15 min in a microcentrifuge, and the supernatants were collected.
Extraction buffer comprises 80 mM
-glycerophosphate (pH 7.4); 20 mM
EDTA; 1 mM dithiothreitol (DTT); 0.1 mM sodium vanadate; 10 mM NaF; 10 µg each of pepstatin, chymostatin, and leupeptin per ml; 3 µM
microcystin; and 1 mM phenylmethylsulfonyl fluoride.
Isolation of PLX1 cDNA. On the basis of sequence information (30), a pair of primers (CGGGGTACCATGGCTCAAGTGGCCGGTA and GGAAGATCTTGCCGAGGCCTTTACGTGT; sequences not underlined are linker sequences) within the PLX1 coding sequence were synthesized and used in PCRs with a Xenopus oocyte cDNA library as the template. An expected 1.8-kb PCR product was cloned into a pOTV vector and identified as a full-length PLX1 cDNA by sequence analysis.
Generation of Plx1(N172A). To prepare a catalytically inactive Plx1 mutant, codon 172 (AAC, coding for asparagine) was mutated to GCC (coding for alanine) (30) in the pOTV-PLX1 construct by PCR using oligonucleotides with the sequences CTCGGAGCCTTGTTCCTTAATGATGAAATG and GAACAAGGCTCCGAGCTTGAGGTCTCT.
Expression and purification of recombinant Plx1 in Sf9
cells.
Full-length PLX1 with C-terminal Flag and 6×His
tags was subcloned into baculovirus transfer vector pVL1393
(Invitrogen, San Diego, Calif.). Insect Sf9 cells expressing Plx1 were
harvested and lysed in buffer A (10 mM HEPES [pH 7.5], 150 mM NaCl)
containing 1 mM EGTA, 0.5% Triton X-100, and 1 mM phenylmethylsulfonyl
fluoride. The clarified lysate was incubated with TALON metal affinity
resin (Clontech, Palo Alto, Calif.) and washed twice with buffer A
containing 1 mM EGTA and 0.5% Triton X-100, twice with
buffer A containing 1 mM EGTA and 0.5% Nonidet P-40 (NP-40), and
with buffer A containing 0.05% Brij 35. Plx1 was eluted with buffer A
containing 250 mM imidazole, dialyzed extensively against 20 mM HEPES
(pH 7.5)-88 mM NaCl-7.5 mM MgCl2-10 mM
-mercaptoethanol, and frozen in small aliquots at
80°C. The same
procedure was used to obtain recombinant, kinase-dead Plx1(N172A).
Generation and affinity purification of rabbit polyclonal
antibodies against Plx1.
Full-length PLX1 with
C-terminal Flag and 6×His tags was subcloned into the bacterial
expression vector pET-3d (Novagen, Madison, Wis.), and the resulting
plasmid was transformed into BL21(DE3)pLysS. The bacteria were grown to
an optical density at 600 nm (OD600) of 0.6 at 37°C in
Luria-Bertani medium containing 100 µg of ampicillin per ml and 25 µg of chloramphenicol per ml. Expression was induced with 0.4 mM
isopropyl-
-D-thiogalactopyranoside for 4 h. The
bacteria were harvested and Plx1 was purified as described above,
except that Plx1 bound to the TALON resin was used directly to immunize two rabbits. Plx1 antibodies were affinity purified as previously described (18) from immune sera on a column of Affi-gel 10 resin (Bio-Rad, Richmond, Calif.) coupled to recombinant Plx1 purified from Sf9 cells. Control immunoglobulin G (IgG) was prepared on a
protein A-agarose (Sigma, St. Louis, Mo.) column from immune sera that
had been depleted of all Plx1-specific antibodies with the Plx1
affinity column. The purified Plx1 antibodies and control IgG were
concentrated with a Centricon 30 (Amicon, Beverly, Mass.) and dialyzed
extensively against 20 mM HEPES (pH 7.5)-88 mM NaCl. Identical results
were obtained with Plx1 antibodies from both rabbits.
Immunoblot analysis. For immunoblot analysis, samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose. The membranes were blocked with 10% nonfat dry milk in 20 mM Tris-HCl (pH 7.5)-137 mM NaCl-0.1% Tween 20, incubated with primary antibody overnight at 4°C, washed, incubated with the appropriate secondary antibody (Jackson ImmunoResearch, West Grove, Pa.) for 1 h at ambient temperature, and washed again. For Cdc25C blots, the equivalent of one-half oocyte was loaded per lane, transfer was done with a semidry apparatus (Pharmacia/LKB, Piscataway, N.J.), and immunoreactive proteins were visualized by enhanced chemiluminescence (Amersham, Arlington Heights, Ill.). Preparation of antiserum against Cdc25C has been described previously (25). For Plx1 blots, the equivalent of one oocyte was loaded per lane, transfer was done with a Hoefer wet transfer apparatus (Pharmacia/LKB), and the blots were developed with an alkaline phosphatase system (Bio-Rad).
Immunoprecipitation and kinase assays.
For quantitation of
histone H1 kinase activity, samples equivalent to one-fifth of an
oocyte were incubated for 10 min at 30°C in a final volume of 30 µl
of kinase buffer (20 mM HEPES [pH 7.2], 2 mM DTT, 10 mM
MgCl2, 0.1 mM EGTA) containing 0.1 mg of bovine serum
albumin per ml, 3.3 µg of the protein kinase A inhibitor protein per
ml, 0.5 mg of histone H1 per ml, and 100 µM
[
-32P]ATP (1 to 5 cpm/fmol). The reactions were
stopped by addition of 15 µl of glacial acetic acid. Samples of 35 µl were spotted onto P81 phosphocellulose squares, and after three
washes with 15% acetic acid, incorporation of radiolabel was
determined by counting Cerenkov radiation. At least 95% of the total
histone H1 kinase activity in egg extracts is due to cyclin B-Cdc2
(34); therefore, assay of total histone H1 kinase activity
reflects the activity of cyclin B-Cdc2.
-32P]ATP (5 to 10 cpm/fmol)-1 mg of
-casein (Sigma) per ml and incubated for 30 min
at 30°C. The reactions were stopped by addition of 20 µl of
four-times-concentrated sample buffer, the reaction mixtures were
incubated at 95°C for 5 min, and 15-µl samples were subjected to
SDS-PAGE. The casein bands were identified by staining, and incorporation of radiolabel was quantified by liquid scintillation spectrometry of the excised bands.
Microinjection and immunofluorescence of Xenopus
embryos.
Embryos were obtained by in vitro fertilization,
dejellied in 2% cysteine (pH 7.8), and cultured in 0.1× MMR as
described previously (19). Embryos were microinjected at the
two-cell stage with 25 nl of anti-Plx1 antibodies (1.5 mg/ml) or
control IgG (1.5 mg/ml), cultured in 0.1× MMR for 4 to 5 h, and
fixed in methanol. Embryos were photographed with a Wild Heerbrugg
dissecting microscope equipped with a 35-mm camera. Immunofluorescence
staining was performed as previously described (11). DNA was
stained with SYTOX Green (Molecular Probes, Inc., Eugene, Oreg.), and
-tubulin was detected with an anti-
-tubulin monoclonal antibody (Sigma) and visualized by Lissamine rhodamine-conjugated donkey anti-mouse IgG antibodies (Jackson ImmunoResearch). Confocal microscopy was performed with an MRC-600 microscope (Bio-Rad). The confocal images
presented here represent projections of Z-series scans.
RESULTS
|
|
|---|
Plx1 is activated during oocyte maturation. To analyze the activity of Plx1, antibodies against recombinant Plx1 purified from bacteria were raised and affinity purified as described in Materials and Methods. Control IgG was prepared from immune sera that had been depleted of all Plx1-specific antibodies. Affinity-purified Plx1 antibodies, but not the control IgG, detected a single polypeptide of 67 kDa in oocyte extracts by immunoblotting (Fig. 1A). Moreover, an increased amount of Plx1 protein could be detected by the Plx1 antibodies in extracts from oocytes that had been microinjected with PLX1 mRNA (data not shown). The plks are able to phosphorylate casein in vitro (8). Therefore, to compare Plx1 activity between resting (stage VI) oocytes in G2 phase and matured, progesterone-treated oocytes that had undergone germinal vesicle breakdown (GVBD) and entered M phase, Plx1 immunoprecipitates were used for casein kinase assays. Plx1 immunoprecipitates prepared from stage VI oocytes (G2 phase) had very low casein kinase activity, whereas immunoprecipitates prepared from matured oocytes that had entered M phase had at least a 30-fold increase in kinase activity toward casein (Fig. 1B). No casein kinase activity was observed in immunoprecipitates prepared with the control IgG. Casein kinase activity in the Plx1 immunoprecipitates was linear with time and amount of extract (data not shown).
|
Plx1 activation is concurrent with Cdc25C and cyclin B-Cdc2 activation. As described in the introduction, in different systems, plks have been implicated either in events at the G2/M transition or in anaphase-telophase events late in mitosis (14, 33). If Plx1 is involved in the G2/M transition in oocytes, its activity should correlate with the activity of other markers of that transition, such as Cdc25C and Cdc2-cyclin B. Therefore, a detailed analysis of Plx1 protein expression and activity was performed during oocyte maturation, a system in which the G2/M transition occurs synchronously after progesterone treatment. The level of Plx1 protein and its electrophoretic mobility were determined by immunoblot analysis, and Plx1 activity was determined by immunoprecipitation and casein kinase assays. Following progesterone addition, the level of Plx1 protein remained constant; however, its activity increased sharply approximately 1 h prior to GVBD in concert with increased histone H1 kinase activity (Fig. 2A and B). This indicates that changes in Plx1 activity are regulated posttranslationally. The increase in Plx1 activity correlated with the appearance of slower-migrating forms upon SDS-PAGE, similar to results reported for mammalian Plk (17) (Fig. 2B). To examine whether phosphorylation is responsible for the activation of Plx1 and its reduced mobility, immunoprecipitates from extracts of mature oocytes were treated with calf intestinal alkaline phosphatase and the effects of dephosphorylation on mobility and casein kinase activity were determined. Immunoprecipitated Plx1 not treated with phosphatase migrated as a slower-migrating form and had high casein kinase activity, whereas a substantial fraction of immunoprecipitated Plx1 treated with phosphatase was converted to the faster-migrating form and fivefold less kinase activity was evident (data not shown). Experiments with 32P-labeled oocytes demonstrated that phosphorylation of Plx1 was on serine and threonine residues. Therefore, in Xenopus oocytes, Plx1 is activated by phosphorylation, as has been reported for plks from other organisms (17, 55).
|
Inhibition of Plx1 activation significantly delays both Cdc25C and cyclin B-Cdc2 activation in progesterone-treated oocytes. To determine whether activation of Plx1 is required for activation of Cdc25C and Cdc2, affinity-purified Plx1 antibody or control IgG was microinjected into stage VI oocytes. The oocytes were exposed to progesterone 2 h later, and the activities of Plx1, Cdc25C, and cyclin B-Cdc2 were monitored. As shown in Fig. 3A, the activation of Plx1 was inhibited almost completely by the Plx1 antibody but not by the control antibody. The inhibition of Plx1 activation was due to the inhibitory effect of Plx1 antibody on the phosphorylation of Plx1 as judged by the lack of a full electrophoretic shift in immunoblots (data not shown). In addition, the Plx1 antibody significantly delayed the activation of both Cdc25C and cyclin B-Cdc2 (Fig. 3A and B). Since Plx1 can phosphorylate and activate Cdc25C in vitro (30), these results support the hypothesis that Plx1 is a relevant Cdc25C-activating kinase involved in entry into mitosis.
|
|
Cdc25C overcomes the inhibitory effect of Plx1 antibody on cyclin B-Cdc2 activation. Previous studies in several laboratories have shown that injection of Cdc25C into stage VI oocytes leads to rapid activation of cyclin B-Cdc2 histone H1 kinase activity and oocyte maturation (reference 37; see Fig. 7). If Plx1 is a Cdc25C-activating kinase, injection of Cdc25C should overcome the inhibitory effect of Plx1 antibody injection on activation of cyclin B-Cdc2. Accordingly, oocytes were injected with Plx1 antibody and then 2 h later with recombinant Cdc25C (23), after which both cyclin B-Cdc2 and Plx1 activities were analyzed. As shown in Fig. 5, Cdc25C rapidly induced cyclin B-Cdc2 activation and, as expected, phosphatase-inactive Cdc25C(C457A) did not. Despite the similar kinetics of Plx1 and Cdc25C activation during progesterone-induced oocyte maturation (Fig. 2), this indicates that Plx1 functions upstream of Cdc25C and cyclin B-Cdc2. In antibody-injected oocytes, Plx1 remained inactive even when cyclin B-Cdc2 was activated following Cdc25C injection.
|
An elevated level of Plx1 accelerates Cdc25C and cyclin B-Cdc2 activation and oocyte maturation. If Plx1 activates Cdc25C in vivo, an elevated level of Plx1 should accelerate Cdc25C activation. Stage VI oocytes were microinjected with recombinant wild-type Plx1, kinase-dead Plx1(N172A), or buffer and subsequently exposed to a threshold level of progesterone (48 nM) which is just sufficient to cause 100% GVBD. Under this condition, the elevated level of wild-type Plx1 accelerated Cdc25C and cyclin B-Cdc2 activation and also GVBD (Fig. 6). Interestingly, kinase-inactive Plx1(N172A) had a dominant-negative effect, delaying the activation of both Cdc25C and cyclin B-Cdc2 (Fig. 6). This result is consistent with the inhibitory effect of Plx1 antibody injection on these events (Fig. 3) and further supports an important role for Plx1 in the pathway of Cdc25C activation.
|
Plx1 is activated during Cdc25C-induced oocyte maturation. Many biological systems contain positive feedback loops. For example, a positive feedback loop exists between Cdc25C and cyclin B-Cdc2 (23) and between Mos synthesis and mitogen-activated protein kinase (40, 48). To investigate whether a positive feedback loop exists between Plx1 and downstream elements, oocytes were injected with recombinant Cdc25C, after which both cyclin B-Cdc2 and Plx1 activities were analyzed. As shown in Fig. 7, wild-type, but not phosphatase-inactive, Cdc25C rapidly induced the activation of both cyclin B-Cdc2 and Plx1, indicating that a positive feedback loop also exists between the Plx1 pathway and downstream components.
|
Plx1 function is required for mitotic spindle organization.
As
described in Fig. 2, Plx1 activity remains high after full activation
of cyclin B-Cdc2 at GVBD, suggesting that it might have additional
functions besides activation of Cdc25C. To investigate this
possibility, the effect of abrogation of Plx1 activity was investigated
in early Xenopus embryos. In early embryonic cleavage cycles
2 to 12, cyclin B-Cdc2 is not tyrosine phosphorylated (9, 19), and thus, Cdc25C function is not required for cyclin B-Cdc2 activation. Instead, Cdc2 activation is controlled by the rate of
translation of cyclin B (19, 43). Therefore, these cell cycles are well suited for investigating Plx1 functions distinct from
Cdc25C activation. In early embryos, Plx1 is significantly deactivated
at fertilization, increases dramatically at the first mitosis, and
shows small oscillations in subsequent cell cycles (Fig.
8A). The decline in
Plx1 activity at each cycle occurred later than the decline in H1
kinase activity. As shown in Fig. 3, injection of anti-Plx1 antibody
into oocytes effectively inhibits the activation of Plx1. Therefore, to
determine whether Plx1 function is important in early embryonic cell
cycles, one blastomere of a two-cell embryo was injected with either
anti-Plx1 IgG or control IgG. The uninjected blastomere served as an
additional control. Injection of Plx1 antibody into the embryo caused
cleavage arrest, whereas control IgG injection had no effect relative
to uninjected controls (Fig. 8B). In various organisms, plks have been
localized to spindles and implicated in mitotic spindle formation or
centrosome replication or function. In addition, spindle abnormalities
or altered cytokinesis events have been seen in other systems after perturbation of plk function (14, 33, 35, 39, 44). In embryonic Xenopus cells, Plx1 was found to be localized to
normal mitotic spindles by confocal microscopy (Fig. 8C), similar to results obtained with mammalian cells (15, 36). As shown in Fig. 8C, early in prophase, Plx1 had a bipolar localization at the
spindle poles and colocalized with
-tubulin. As shown in Fig. 8D,
inhibition of Plx1 resulted in monopolar spindles with altered patterns
of
-tubulin associated with a radial distribution of chromosomes
around the pole. Monopolar spindles have also been described in
Drosophila embryos with loss-of-function mutations in
polo (39) and in mammalian cells after injection
of anti-Plk1 antibodies (32). Together, these results
indicate that Plx1 function is required for spindle organization, an
event that occurs in late mitosis, and also for activation of Cdc25C,
which occurs in the initial stages of mitosis.
|
DISCUSSION
|
|
|---|
The results reported here establish that the activity of Plx1 is cell cycle regulated and involved in the G2/M transition during Xenopus oocyte maturation. The inhibitory effects of Plx1 antibody injection, as well as the effects of wild-type and kinase-dead Plx1 on progesterone-induced Cdc25C activation, demonstrate that Plx1 functions in the Cdc25C activation pathway. Several lines of evidence support the hypothesis that these effects occur due to direct phosphorylation of Cdc25C by Plx1. First, Cdc25C is a substrate for Plx1 in vitro (30; our unpublished data). Second, activation of Plx1 correlates exactly with activation of Cdc25C during both meiosis I and meiosis II and Plx1 antibody or kinase-dead Plx1 significantly delays the phosphorylation and activation of Cdc25C. Third, Cdc25C itself can overcome the inhibitory effect of Plx1 antibody. These results support the hypothesis that Plx1 could be a trigger kinase, also termed kinase X (24), that initiates the positive feedback loop between Cdc25C and cyclin B-Cdc2. The existence of a trigger kinase had been predicted from studies in which initial activation of Cdc25C occurred prior to or in the absence of cyclin B-Cdc2 (24). The results shown here indicate that Plx1 may be a trigger kinase, but they do not exclude the possibility that other kinases also function as trigger kinases. Since injection of Plx1 antibody almost completely inhibited Plx1 activity yet did not completely block Cdc25C activation, it is likely that, in addition to Plx1 and cyclin B-Cdc2, other protein kinases also contribute to Cdc25C activation. Such a situation would not be unusual, since multiple protein kinases control the activity of the protein kinase Wee1 (26, 46, 54). It remains to be determined whether Plx1 can also phosphorylate and inhibit Wee1 or Myt1, which might further enhance a trigger kinase function governing entry into mitosis.
The results presented here indicate that the regulatory element upstream of Plx1 in the pathway that activates Cdc25C is a serine/threonine kinase. In both Drosophila and human cells, an electrophoretic shift of plk similar to that described here has been reported (17, 55), and a variety of evidence indicates that this shift is due to phosphorylation. This suggests that a general activation mechanism involving a protein kinase cascade, with a kinase that activates Plx1, has been conserved during evolution. Plx1 contains a single consensus site for phosphorylation by cyclin B-Cdc2, but phosphorylation in vitro by cyclin B-Cdc2 does not activate human Plk1 (17) or Plx1 (our unpublished data). At present, there are no genetic or biochemical candidates for a Plx1-activating kinase, but its eventual identification should contribute to further understanding of the pathway of Cdc25C activation and its role in the G2/M transition and the DNA replication checkpoint. In mammalian cells, changes in the abundance of Plk1 have been noted during the cell cycle and may also contribute to Plk1 activity (15, 17, 36), but in Xenopus oocyte and embryonic cell cycles, no change in the abundance of Plx1 was observed (Fig. 2 and data not shown).
Plks are members of a small subset of protein kinases that generate phosphoepitopes recognized by the MPM-2 antibody (3, 27, 53). This antibody recognizes a proline-directed epitope and reacts with a large number of proteins phosphorylated specifically at mitosis, which are located on several important mitotic structures, including centrosomes and kinetochores (56, 57). Cdc25C has been reported to exhibit MPM-2 immunoreactivity in mitosis, and both cyclin B-Cdc2 and Plx1 phosphorylate Cdc25C in vitro at MPM-2 epitopes (28, 30). Since Plx1 remains active during oocyte maturation even after entry into M phase, it seems likely that Plx1 also has other functions later in M phase which may involve MPM-2 immunoreactive components on centrosomes and spindles. Consistent with this idea, inhibition of Plx1 function in embryonic cleavage cycles disrupted bipolar-spindle formation and resulted in monopolar spindles displaying a radial array of chromosomes. Moreover, Plx1 activity remained high for a significant period after the metaphase/anaphase transition (Fig. 8A), consistent with a role in spindle assembly. Spindle abnormalities have been seen in other systems when plk function is impaired (32, 35, 39, 44), suggesting that plk may regulate centrosome or spindle pole body duplication or function, but the exact function of plk during spindle assembly has not yet been elucidated. In lower organisms, such as budding yeast and D. melanogaster, plk function has been evident only in late mitotic events involving spindle formation and cytokinesis (14, 33). As reported here, Plx1 also performs similar functions in X. laevis. In addition, Plx1 is important earlier in mitosis for the initial activation of Cdc25C, fulfilling the criteria expected for a trigger kinase. There are several reasons why this earlier effect may not have been observed in yeast and D. melanogaster. First, in budding yeast, cyclin B-Cdc2 activation is not normally controlled by Cdc25 activation and tyrosine dephosphorylation (1, 38). In fission yeast and D. melanogaster, Cdc25 activation is crucial but its activity level is controlled by transcription rather than by posttranslational modification (5, 41). In human cells, Cdc25C activity is controlled by phosphorylation, as in X. laevis (21, 25, 31), but since inhibition of plk function only delays mitosis, the plk loss-of-function phenotype was observed primarily as abnormalities of spindle organization in various cell lines (32). Interestingly, however, in nonimmortalized mammalian cells, Plk1 antibody injection increases the fraction of cells in G2, perhaps reflecting impairment of the Cdc25C activation pathway (32).
The finding here that Plx1 functions at two discrete points in mitosis is consistent with the pleiotropic action of other cell cycle-regulated protein kinases. For example, cyclin B-Cdc2 is required not only to initiate the G2/M transition but also to maintain metaphase (22). The Mos-mitogen-activated protein kinase cascade is required in X. laevis not only to cause cell cycle progression in meiosis I but also to cause metaphase arrest in meiosis II (49, 50). In the case of Plx1, the progesterone-treated oocyte is well suited for analysis of its role in Cdc25C activation, whereas embryos offer a different type of cell cycle, in which effects of Plx1 on spindle organization are evident. Further work using both of these systems should enhance elucidation of plk functions that are conserved during evolution.
ACKNOWLEDGMENTS
|
|
|---|
We thank Sang H. Kim for the purified Cdc25C preparations, Kyung S. Lee and R. L. Erikson for the gift of Plk1 constructs and helpful suggestions, and Jill C. Sible for helpful discussions and critical reading of the manuscript. The baculovirus-infected Sf9 cells were produced in the tissue culture/monoclonal antibody core facility at the University of Colorado Cancer Center.
This work was supported by a grant from the NIH (GM26743). Y.-W.Q. is an Associate and J.L.M. an Investigator of the Howard Hughes Medical Institute.
FOOTNOTES
* Corresponding author. Mailing address: Howard Hughes Medical Institute and Department of Pharmacology, University of Colorado School of Medicine, Biomedical Research Bldg., Room 433, 4200 Ninth Ave., Box C-236, Denver, CO 80262-0236. Phone: (303) 315-7075. Fax: (303) 315-7160. E-mail: mallerj{at}essex.uchsc.edu.
REFERENCES
|
|
|---|
| 1. | Amon, A., U. Surana, I. Muroff, and K. Nasmyth. 1992. Regulation of p34CDC28 tyrosine phosphorylation is not required for entry into mitosis in S. cerevisiae. Nature 355:368-371[Medline]. |
| 2. | Dasso, M., and J. W. Newport. 1990. Completion of DNA replication is monitored by a feedback system that controls the initiation of mitosis in vitro: studies in Xenopus. Cell 61:811-823[Medline]. |
| 3. |
Davis, F. M.,
T. Y. Tsao,
S. K. Fowler, and P. N. Rao.
1983.
Monoclonal antibodies to mitotic cells.
Proc. Natl. Acad. Sci. USA
80:2926-2930 |
| 4. | Dunphy, W. G., and A. Kumagai. 1991. The cdc25 protein contains an intrinsic phosphatase activity. Cell 67:189-196[Medline]. |
| 5. | Edgar, B. A., D. A. Lehman, and P. H. O'Farrell. 1994. Transcriptional regulation of string (cdc25): a link between developmental programming and the cell cycle. Development 120:3131-3143[Abstract]. |
| 6. |
Elledge, S. J.
1996.
Cell cycle checkpoints: preventing an identity crisis.
Science
274:1664-1672 |
| 7. | Enoch, T., and P. Nurse. 1991. Coupling M phase and S phase: controls maintaining the dependence of mitosis on chromosome replication. Cell 65:921-923[Medline]. |
| 8. | Fenton, B., and D. M. Glover. 1993. A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos. Nature 363:637-640[Medline]. |
| 9. |
Ferrell, J. E., Jr.,
M. Wu,
J. C. Gerhart, and G. S. Martin.
1991.
Cell cycle tyrosine phosphorylation of p34cdc2 and a microtubule-associated protein kinase homolog in Xenopus oocytes and eggs.
Mol. Cell. Biol.
11:1965-1971 |
| 10. |
Furnari, B.,
N. Rhind, and P. Russell.
1997.
Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase.
Science
277:1495-1497 |
| 11. |
Gard, D. L.,
S. Hafezi,
T. Zhang, and S. J. Doxsey.
1990.
Centrosome duplication continues in cycloheximide-treated Xenopus blastulae in the absence of a detectable cell cycle.
J. Cell Biol.
110:2033-2042 |
| 12. | Gautier, J., T. Matsukawa, P. Nurse, and J. Maller. 1989. Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle. Nature 339:626-629[Medline]. |
| 13. | Gautier, J., M. J. Solomon, R. N. Booher, J. F. Bazan, and M. W. Kirschner. 1991. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67:197-211[Medline]. |
| 14. |
Glover, D. M.,
H. Ohkura, and A. Tavares.
1996.
Polo kinase: the choreographer of the mitotic stage?
J. Cell Biol.
135:1681-1684 |
| 15. |
Golsteyn, R. M.,
K. E. Mundt,
A. M. Fry, and E. A. Nigg.
1995.
Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function.
J. Cell Biol.
129:1617-1628 |
| 16. | Gould, K. L., and P. Nurse. 1989. Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis. Nature 342:39-45[Medline]. |
| 17. |
Hamanaka, R.,
M. R. Smith,
P. M. O'Connor,
S. Maloid,
K. Mihalic,
J. L. Spivak,
D. L. Longo, and D. K. Ferris.
1995.
Polo-like kinase is a cell cycle-regulated kinase activated during mitosis.
J. Biol. Chem.
270:21086-21091 |
| 18. | Harlow, E., and D. Lane. 1988. In Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 19. | Hartley, R. S., R. E. Rempel, and J. L. Maller. 1996. In vivo regulation of the early embryonic cell cycle in Xenopus. Dev. Biol. 173:408-419[Medline]. |
| 20. |
Hartwell, L. H., and T. A. Weinert.
1989.
Checkpoints: controls that ensure the order of cell cycle events.
Science
246:629-634 |
| 21. | Hoffmann, I., P. R. Clarke, M. J. Marcote, E. Karsenti, and G. Draetta. 1993. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J. 12:53-63[Medline]. |
| 22. | Holloway, S. L., M. Glotzer, R. W. King, and A. W. Murray. 1993. Anaphase is initiated by proteolysis rather than by the inactivation of maturation-promoting factor. Cell 73:1393-1402[Medline]. |
| 23. | Izumi, T., and J. L. Maller. 1993. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol. Biol. Cell 4:1337-1350[Abstract]. |
| 24. | Izumi, T., and J. L. Maller. 1995. Phosphorylation and activation of the Xenopus Cdc25 phosphatase in the absence of Cdc2 and Cdk2 kinase activity. Mol. Biol. Cell 6:215-226[Abstract]. |
| 25. | Izumi, T., D. H. Walker, and J. L. Maller. 1992. Periodic changes in phosphorylation of the Xenopus cdc25 phosphatase regulate its activity. Mol. Biol. Cell 3:927-939[Abstract]. |
| 26. | Kornbluth, S., B. Sebastian, T. Hunter, and J. Newport. 1994. Membrane localization of the kinase which phosphorylates p34cdc2 on threonine 14. Mol. Biol. Cell 5:273-282[Abstract]. |
| 27. |
Kuang, J., and C. L. Ashorn.
1993.
At least two kinases phosphorylate the MPM-2 epitope during Xenopus oocyte maturation.
J. Cell Biol.
123:859-868 |
| 28. | Kuang, J., C. L. Ashorn, M. Gonzalez-Kuyvenhoven, and J. E. Penkala. 1994. cdc25 is one of the MPM-2 antigens involved in the activation of maturation-promoting factor. Mol. Biol. Cell 5:135-145[Abstract]. |
| 29. | Kumagai, A., and W. G. Dunphy. 1991. The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. Cell 64:903-914[Medline]. |
| 30. | Kumagai, A., and W. G. Dunphy. 1996. Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273:1377-1380[Abstract]. |
| 31. | Kumagai, A., and W. G. Dunphy. 1992. Regulation of the cdc25 protein during the cell cycle in Xenopus extracts. Cell 70:139-151[Medline]. |
| 32. |
Lane, H. A., and E. A. Nigg.
1996.
Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.
J. Cell Biol.
135:1701-1713 |
| 33. | Lane, H. A., and E. A. Nigg. 1997. Cell-cycle control: POLO-like kinases join the outer circle. Trends Cell Biol. 7:63-68. [Medline] |
| 34. |
Langan, T. A.,
J. Gautier,
M. Lohka,
R. Hollingsworth,
S. Moreno,
P. Nurse,
J. Maller, and R. A. Sclafani.
1989.
Mammalian growth-associated H1 histone kinase: a homolog of cdc2+/CDC28 protein kinases controlling mitotic entry in yeast and frog cells.
Mol. Cell. Biol.
9:3860-3868 |
| 35. | Lee, K. S., and R. L. Erikson. 1997. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol. Cell. Biol. 17:3408-3417[Abstract]. |
| 36. | Lee, K. S., Y. L. Yuan, R. Kuriyama, and R. L. Erikson. 1995. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol. Cell. Biol. 15:7143-7151[Abstract]. |
| 37. | Lee, M. S., S. Ogg, M. Xu, L. L. Parker, D. J. Donoghue, J. L. Maller, and H. Piwnica-Worms. 1992. cdc25+ encodes a protein phosphatase that dephosphorylates p34cdc2. Mol. Biol. Cell 3:73-84[Abstract]. |
| 38. |
Lew, D. J., and S. I. Reed.
1995.
A cell cycle checkpoint monitors cell morphogenesis in budding yeast.
J. Cell Biol.
129:739-749 |
| 39. |
Llamazares, A.,
A. Moreira,
A. Tavares,
C. Girdam,
B. A. Spruce,
C. Gonzales,
R. E. Karess,
D. M. Glover, and C. E. Sunkel.
1991.
polo encodes a protein kinase homolog required for mitosis in Drosophila.
Genes Dev.
5:2153-2165 |
| 40. | Matten, W. T., T. D. Copeland, N. G. Ahn, and G. F. Vande Woude. 1996. Positive feedback between MAP kinase and Mos during Xenopus oocyte maturation. Dev. Biol. 179:485-492[Medline]. |
| 41. | Moreno, S., P. Nurse, and P. Russell. 1990. Regulation of mitosis by cyclic accumulation of p80Cdc25 mitotic inducer in fission yeast. Nature 344:549-552[Medline]. |
| 42. |
Mueller, P. R.,
T. R. Coleman,
A. Kumagai, and W. G. Dunphy.
1995.
Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15.
Science
270:86-90 |
| 43. | Murray, A. W., M. J. Solomon, and M. W. Kirschner. 1989. The role of cyclin synthesis and degradation in the control of maturation promoting factor activity. Nature 339:280-286[Medline]. |
| 44. |
Ohkura, H.,
I. M. Hagan, and D. M. Glover.
1995.
The conserved Schizosaccharomyces pombe kinase plo1, required to form a bipolar spindle, the actin ring, and septum, can drive septum formation in G1 and G2 cells.
Genes Dev.
9:1059-1073 |
| 45. |
Parker, L. L.,
S. Atherton-Fessler, and H. Piwnica-Worms.
1992.
p107wee1 is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15.
Proc. Natl. Acad. Sci. USA
89:2917-2921 |
| 46. | Parker, L. L., S. A. Walter, P. G. Young, and H. Piwnica-Worms. 1993. Phosphorylation and inactivation of the mitotic inhibitor Wee1 by the nim1/cdr1 kinase. Nature 363:736-738[Medline]. |
| 47. |
Peng, C. Y.,
P. R. Graves,
R. S. Thoma,
Z. Wu,
A. S. Shaw, and H. Piwnica-Worms.
1997.
Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216.
Science
277:1501-1505 |
| 48. | Roy, L. M., O. Haccard, T. Izumi, B. G. Lattes, A. L. Lewellyn, and J. L. Maller. 1996. Mos proto-oncogene function during oocyte maturation in Xenopus. Oncogene 12:2203-2211[Medline]. |
| 49. | Sagata, N., M. Oskarsson, T. Copeland, J. Brumbaugh, and G. F. Vande Woude. 1988. Function of c-mos proto-oncogene product in meiotic maturation in Xenopus oocytes. Nature 335:519-525[Medline]. |
| 50. | Sagata, N., N. Watanabe, G. F. Vande Woude, and Y. Ikawa. 1989. The c-mos proto-oncogene product is a cytostatic factor responsible for meiotic arrest in vertebrate eggs. Nature 342:512-518[Medline]. |
| 51. |
Sanchez, Y.,
C. Wong,
R. S. Thoma,
R. Richman,
Z. Wu,
H. Piwnica-Worms, and S. J. Elledge.
1997.
Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25.
Science
277:1497-1501 |
| 52. | Smythe, C., and J. W. Newport. 1992. Coupling of mitosis to the completion of S phase in Xenopus occurs via modulation of the tyrosine kinase that phosphorylates p34cdc2. Cell 68:787-797[Medline]. |
| 53. | Taagepera, S., P. Dent, J. H. Her, T. W. Sturgill, and G. J. Gorbsky. 1994. The MPM-2 antibody inhibits mitogen-activated protein kinase activity by binding to an epitope containing phosphothreonine-183. Mol. Biol. Cell 5:1243-1251[Abstract]. |
| 54. | Tang, Z., T. R. Coleman, and W. G. Dunphy. 1993. Two distinct mechanisms for negative regulation of the Wee1 protein kinase. EMBO J. 12:3427-3436[Medline]. |
| 55. | Tavares, A. A., D. M. Glover, and C. E. Sunkel. 1996. The conserved mitotic kinase polo is regulated by phosphorylation and has preferred microtubule-associated substrates in Drosophila embryo extracts. EMBO J. 15:4873-4883[Medline]. |
| 56. | Vandre, D. D., F. M. Davis, P. N. Rao, and G. G. Borisy. 1986. Distribution of cytoskeletal proteins sharing a conserved phosphorylated epitope. Eur. J. Cell Biol. 41:72-81[Medline]. |
| 57. |
Westendorf, J. M.,
P. N. Rao, and L. Gerace.
1994.
Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope.
Proc. Natl. Acad. Sci. USA
91:714-718 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»